If you've had a standard preconception work-up, it most likely included thyroid function, iron studies and possibly a reproductive hormone panel. What many panels still don't include is homocysteine, a marker that continues to appear in fertility and pregnancy research.
What homocysteine is
Homocysteine is an amino acid produced during normal metabolism. Under healthy conditions, it is rapidly converted into other compounds, primarily methionine or cysteine, with the help of B vitamins (folate, B12 and B6). When this conversion works efficiently, circulating homocysteine remains low. When it is impaired, levels can rise.
This conversion sits within a broader biochemical process called methylation, the same pathway in which genes such as MTHFR play a role. Homozygosity for the MTHFR C677T variant (TT genotype) is associated with reduced enzyme activity and elevated homocysteine, particularly when folate status is low (1,7). Heterozygous C677T (CT) and A1298C genotypes alone are not consistently associated with clinically significant elevations in homocysteine (7,8). Homocysteine measurement therefore serves as one functional indicator of how well this pathway is operating at any given time.
What the research shows, and what it doesn't
A body of observational research has explored associations between elevated homocysteine and several aspects of reproductive health. The strongest and most consistent evidence links elevated homocysteine to implantation failure and recurrent pregnancy loss: a 2026 meta-analysis of 13 case-control studies (n = 3,078) reported a pooled odds ratio of 3.46 (95% CI 2.33–5.14) for unexplained recurrent pregnancy loss in women with hyperhomocysteinaemia (2). A prospective cohort (n = 812) identified preconception homocysteine ≥ 10.71 µmol/L as associated with increased early pregnancy loss risk (adjusted OR 1.27) (3). A further prospective study (n = 1,011 IVF/ICSI cycles) found elevated homocysteine negatively associated with clinical pregnancy and implantation rate, though notably not with oocyte number, fertilisation rate, cleavage rate or high-quality embryo rate, and this effect reached statistical significance only in MTHFR 677TT carriers (1).
Associations between elevated homocysteine and oocyte quality, sperm quality and embryo morphology have been proposed on mechanistic grounds and explored in smaller studies, but this evidence remains preliminary (4).
It is important to be clear about the nature of this evidence overall:
- Most studies are observational (case-control, cross-sectional or prospective cohort), meaning they can identify associations but not confirm causation.
- Effect sizes vary across studies and populations.
- Elevated homocysteine is one of many markers that have been linked to reproductive outcomes; it is not established as a standalone cause of miscarriage or infertility.
- A single homocysteine result does not predict what will happen in any individual pregnancy.
- Notably, one prospective cohort found that homocysteine, rather than folate itself, predicted pregnancy loss risk even in folate-replete women, suggesting the marker may capture metabolic information beyond simple folate adequacy (10).
What makes homocysteine noteworthy within this landscape is its practical profile: it is inexpensive to measure and, in many individuals, responsive to changes in B-vitamin intake and dietary pattern. This gives it a potential role as a modifiable marker within preconception care, though intervention trials specifically demonstrating that lowering homocysteine improves pregnancy outcomes remain limited (see below).
The genetics-to-function connection
This is where methylation genetics and homocysteine testing work as complementary assessments rather than interchangeable ones.
An MTHFR Blood Test or the broader Genetic Methylation Test identifies whether you carry variants that may affect folate metabolism. This provides context about predisposition, but genotype alone does not tell you how the pathway is functioning right now, because gene expression is influenced by diet, environment and other individual factors.
The Homocysteine Blood Test provides a functional snapshot: whether those genetic variants (or dietary shortfalls, or other factors) are currently resulting in elevated homocysteine. In short, genetics shows predisposition; homocysteine shows current status.
It is worth emphasising that the MTHFR C677T TT genotype is the variant with consistent evidence for clinically meaningful homocysteine elevation; A1298C alone has not been shown to significantly raise homocysteine in population studies (7,8).
Why this marker is considered modifiable
B-vitamin supplementation (folate, B12 and B6) reliably lowers homocysteine. In one interventional study of 16 women with recurrent pregnancy loss and MTHFR mutations, methylfolate plus B6 and B12 reduced homocysteine from 19.4 ± 5.3 to 6.9 ± 2.2 µmol/L; seven of the 16 participants subsequently achieved a live birth (5). A retrospective cohort study (n = 269) found that 5-methyltetrahydrofolate plus B12 and B6 supplementation was associated with higher clinical pregnancy (OR 2.03) and live birth (OR 1.83) rates compared with folic acid alone in women undergoing assisted reproduction (6).
However, these are small and/or retrospective studies. Robust randomised controlled trial evidence proving that homocysteine-lowering itself, rather than B-vitamin supplementation in general, causally improves live birth rates is still lacking. This is an active area of research.
It is also worth noting that not all elevated homocysteine responds to B-vitamin intervention alone. In some cases, factors such as vitamin B12 malabsorption, renal impairment or other metabolic conditions may be involved, and clinical guidance is appropriate (9).
Where this fits for practitioners
Some fertility specialists advocate for preconception homocysteine testing given its associations with pregnancy loss, though this is not yet a standard component of major society infertility guidelines (9). For practitioners working in women's health, fertility or preconception care, homocysteine and methylation genetic testing are worth considering as a complementary pair, particularly for clients already enquiring about MTHFR, those with a history of recurrent pregnancy loss, or those with unexplained fertility challenges. Both can be ordered without a GP referral, and results are delivered through a single dashboard for ease of interpretation alongside the client. Broader reproductive hormone markers can be layered in through a Fertility Test or the full Women's Health & Fertility range, where a wider preconception picture is clinically indicated.
A note on recurrent pregnancy loss
If you or a client has experienced recurrent miscarriage (typically defined as three or more consecutive losses), investigation by a fertility specialist or GP is the appropriate first step. Homocysteine and methylation markers may form a useful part of the broader clinical work-up, but they sit alongside, not in place of, thorough clinical assessment including thrombophilia screening, uterine investigations and immunological evaluation as indicated.
The short version
Most preconception check-ups focus on hormones. Homocysteine, and the methylation genetics behind it, is a marker worth including in that conversation: inexpensive, testable without referral, and one of the more modifiable pieces of the preconception picture currently available. The evidence base linking elevated homocysteine to implantation failure and recurrent pregnancy loss is consistent across observational studies and meta-analysis (1–3), though causal proof from intervention trials is still awaited. For the MTHFR-curious, functional testing via homocysteine adds a layer that genotype alone cannot provide.
Medical disclaimer
This article is general information only and does not replace advice from your doctor or fertility specialist. Homocysteine and methylation markers provide information about broader metabolic patterns, not a diagnosis. Elevated homocysteine is associated with, but not established as a standalone cause of, miscarriage. Anyone experiencing recurrent pregnancy loss, or with concerns about fertility or pregnancy, should speak with a GP or fertility specialist directly.
